Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
• To compare the efficacy of the following 2 treatment paradigms in subjects who have achieved an inadequate (Investigator’s Global Assessment [IGA] ≥2) response to ustekinumab at Week 16: - Switching to guselkumab treatment. - Remaining on ustekinumab treatment. • To assess the safety and tolerability of guselkumab in subjects with moderate to severe plaque-type psoriasis and an inadequate (IGA≥2) response to ustekinumab at Week 16.
Critère d'inclusion
- Moderate to severe plaque-type psoriasis